Neuroprotection in vascular dementia: A future path

Ingmar Skoog, Amos D. Korczyn, Alla Guekht*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The burden of cognitive disorders is likely to increase over the coming years due to both increased longevity and altered risk factor patterns, arising from changes in lifestyle, healthcare and society. Vascular dementia with its underlying heterogeneous pathology, is a challenge for clinicians, and is frequently further aggravated by overlap with other neurodegenerative processes. Current Alzheimer's disease drugs have had limited clinical efficacy in treating vascular dementia and none have been approved by major regulatory authorities specifically for this disease. Moving forward, a valid choice may be a multimodal therapy, as has already been successfully proven in Alzheimer's disease. Actovegin, a hemodialysate derived from calf blood, has been shown to have effects on a variety of cellular processes and a recent experimental study has revealed its neuroprotective mechanisms of action. These data, coupled with positive results from clinical trials in mixed dementia populations, have served as a foundation for the design of a new trial investigating the efficacy and disease-modifying effects of Actovegin in post-stroke cognitive impairment.

Original languageEnglish
Pages (from-to)232-236
Number of pages5
JournalJournal of the Neurological Sciences
Volume322
Issue number1-2
DOIs
StatePublished - 15 Nov 2012

Keywords

  • Pathology
  • Post-stroke cognitive impairment
  • Therapy
  • Vascular cognitive impairment
  • Vascular dementia

Fingerprint

Dive into the research topics of 'Neuroprotection in vascular dementia: A future path'. Together they form a unique fingerprint.

Cite this